Evidence map›Paper›PMID 28892092›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2017

High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence.

Brad E Wasserman, Daniel E Carvajal-Hausdorf, Kenneth Ho, Wendy Wong, Natalie Wu, Victor C Chu, Edwin W Lai, Jodi M Weidler, Michael Bates, Veronique Neumeister and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Evaluation ofCancers · 2023
    Article
  6. XPERTEcancermedicalscience · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Brad E WassermanDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Daniel E Carvajal-HausdorfDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Kenneth HoDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Wendy WongDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Natalie WuDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Victor C ChuDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Edwin W LaiDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Jodi M WeidlerDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Michael BatesDivision of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Veronique NeumeisterDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Yale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Optimal Predictors of Response to TrastuzumabR01CA139431 · NCI · YALE UNIVERSITY · PI HARRIS, LYNDSAY NORINE, RIMM, DAVID L · 2009 to 2010
$1.2M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA139431
6 · The paper itself

Abstract

Historically, mRNA measurements have been tested on several commercially available platforms, but none have gained broad acceptance for assessment of HER2. An mRNA measurement, as a continuous value, has the potential for use in adjudication of the equivocal category. Here we use a real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay in a closed, single-use cartridge, automated system. Multiple cores (1 mm in diameter) were retrospectively collected from 80 formalin-fixed paraffin-embedded (FFPE) tissue blocks with invasive breast cancer seen by Yale Pathology Labs between 1998 and 2011. Tissue cores were processed with a FFPE lysis kit to create lysates that were tested with the automated RT-qPCR assay. Results for IHC and FISH were extracted from the pathology reports and quantitative immunofluorescence (QIF) for each case was measured as previously described. Quality control testing showed that the GX platform RT-qPCR shows no case to case cross contamination on material from routine histology practices. Concordance between RT-qPCR and IHC/FISH was 91.25% (sensitivity=0.87; specificity=0.94; PPV=0.89; NPV=0.92) using a pre-defined delta Ct cut-off (dCt≥-1) for HER2. Concordance (OPA) between RT-qPCR and QIF was 94% (sensitivity=0.90; specificity=0.96; PPV=0.93; NPV=0.94) using dCt≥-1 and a previously defined cut-point for positivity by QIF. In conclusion, the closed system RT-qPCR assay shows >90% concordance with the ASCO/CAP HER2 IHC/FISH scoring. Additionally, the RT-qPCR assay is highly concordant (94%) with the continuous variable HER2 QIF assay, and may better reflect the true continuum of HER2 receptor status in invasive breast cancer. These initial results suggest that fast, closed system molecular assays may have future value for the adjudication of the ASCO/CAP HER2 equivocal category or possibly routine usage in time constrained or low resource settings.

Indexed as

Breast NeoplasmsImmunohistochemistryIn Situ Hybridization, FluorescenceReal-Time Polymerase Chain ReactionBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleFluorescent Antibody TechniqueHumansReproducibility of ResultsRetrospective StudiesRNA, MessengerBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesRNA, Messenger

Identifiers

PMID28892092
PMCPMC5711560
OpenAlexW2754042392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.